Consistently, the inhibition of FXR functions has been associated with DNA damage and impaired cell proliferation, and the loss of FXR has been markedly correlated with aggressive tumor phenotypes and poor prognosis in patients with HCC and CC [81,82], while relative activation by FXR agonist (obeticholic acid) represents a promising anti-cancerogenic frontier to explore in the field of hepatic tumors [81,83]. The gene discussed is NR1H4; the disease is cholangiocarcinoma.